Moberg Pharma AB interim report January - September 2015
CONTINUED GROWTH AND DOUBLING OF PROFITPERIOD (JAN-SEP 2015) · Revenue MSEK 231.9 (155.7) · EBITDA MSEK 42.4 (21.7) · EBITDA for Commercial Operations MSEK 59.9 (34.2) · Operating profit (EBIT) MSEK 34.1 (15.8) · Net profit after tax MSEK 25.1 (12.5) · Earnings per share SEK 1.76 (0.97) · Operating cash flow per share SEK 2.03 (0.80) THIRD QUARTER (JUL-SEP 2015) · Revenue MSEK 66.6 (50.3) · EBITDA MSEK 13.8 (7.3) · EBITDA for Commercial Operations MSEK 18.1 (11.7) · Operating profit (EBIT) MSEK 10.9 (5.3) · Net profit after tax MSEK 8.8 (4.4) ·